CAMBRIDGE, Mass. — MEDIPOST Inc. said it has submitted an Investigational New Drug (IND) amendment to the U.S. Food and Drug Administration to support the initiation of a Phase III clinical trial evaluating its investigational cell therapy for knee osteoarthritis.
The submission represents a key step in the company’s U.S. clinical development program and is intended to enable a late-stage study of an allogeneic, umbilical cord blood-derived mesenchymal stem cell therapy designed to treat symptomatic cartilage defects in patients with knee osteoarthritis. MEDIPOST expects patient enrollment for the Phase III trial to begin in the first half of 2026.
“Submitting this IND amendment marks an important step toward advancing our U.S. clinical program,” said Edward Ahn, PhD, Chief Executive Officer of MEDIPOST Inc. “Knee osteoarthritis continues to place a significant burden on patients, with limited treatment options that address the underlying disease. Through this study, our focus is on generating rigorous clinical evidence that could support a new treatment approach for people living with this condition.”
Knee osteoarthritis remains one of the leading causes of chronic pain and reduced mobility worldwide, underscoring the need for therapies that extend beyond symptom management. The planned Phase III study is designed to further evaluate the potential of regenerative cell therapy to address cartilage damage associated with the condition.
“Filing an IND amendment reflects our long-term commitment to advancing science that has the potential to make a meaningful difference for patients,” Ahn said.
